Compare NMM & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NMM | NVCR |
|---|---|---|
| Founded | 2007 | 2000 |
| Country | Greece | Switzerland |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.0B |
| IPO Year | 2007 | 2015 |
| Metric | NMM | NVCR |
|---|---|---|
| Price | $81.35 | $15.06 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $85.00 | $28.08 |
| AVG Volume (30 Days) | 93.1K | ★ 1.8M |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | ★ 0.34% | N/A |
| EPS Growth | N/A | ★ 21.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $655,353,000.00 |
| Revenue This Year | $5.57 | $7.72 |
| Revenue Next Year | $3.66 | $6.74 |
| P/E Ratio | $7.24 | ★ N/A |
| Revenue Growth | N/A | ★ 8.28 |
| 52 Week Low | $41.66 | $9.82 |
| 52 Week High | $80.97 | $21.45 |
| Indicator | NMM | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 64.12 | 44.54 |
| Support Level | $69.21 | $14.85 |
| Resistance Level | $80.69 | $15.46 |
| Average True Range (ATR) | 2.50 | 1.12 |
| MACD | 0.53 | -0.16 |
| Stochastic Oscillator | 79.97 | 3.67 |
Navios Maritime Partners LP is an international owner and operator of dry cargo and tanker vessels. Its vessels are generally chartered-out under short-term, medium-term and long-term time charters with an average remaining charter duration of approximately 2.1 years to a group of counterparties. Its fleet consisted of dry bulk vessels, containerships and tanker vessels, including two newbuilding capesize vessels, newbuilding containerships and newbuilding tankers. It operates in single segment.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.